human lecs Search Results


90
Lonza human primary lecs
Human Primary Lecs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human primary lecs/product/Lonza
Average 90 stars, based on 1 article reviews
human primary lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Lonza adult human dermal lecs
Adult Human Dermal Lecs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adult human dermal lecs/product/Lonza
Average 90 stars, based on 1 article reviews
adult human dermal lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
BioMimetic Therapeutics human dermal microvascular lymphatic endothelial cells (lecs)
(A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic <t>endothelial</t> identity and cell morphology in the channel. (B) Morphologic changes in human dermal <t>microvascular</t> blood endothelial cells (BECs) with lymphatic endothelial cells <t>(LECs)</t> after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.
Human Dermal Microvascular Lymphatic Endothelial Cells (Lecs), supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dermal microvascular lymphatic endothelial cells (lecs)/product/BioMimetic Therapeutics
Average 90 stars, based on 1 article reviews
human dermal microvascular lymphatic endothelial cells (lecs) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Lonza human neonatal primary microdermal lecs
(A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic <t>endothelial</t> identity and cell morphology in the channel. (B) Morphologic changes in human dermal <t>microvascular</t> blood endothelial cells (BECs) with lymphatic endothelial cells <t>(LECs)</t> after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.
Human Neonatal Primary Microdermal Lecs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human neonatal primary microdermal lecs/product/Lonza
Average 90 stars, based on 1 article reviews
human neonatal primary microdermal lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
BioVector Inc human lecs sra01/04
(A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic <t>endothelial</t> identity and cell morphology in the channel. (B) Morphologic changes in human dermal <t>microvascular</t> blood endothelial cells (BECs) with lymphatic endothelial cells <t>(LECs)</t> after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.
Human Lecs Sra01/04, supplied by BioVector Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lecs sra01/04/product/BioVector Inc
Average 90 stars, based on 1 article reviews
human lecs sra01/04 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AngioBio Inc human neonatal microdermal lecs
Aqueous humor induced the regression of lymphatic tubes formed by human <t>microdermal</t> lymphatic endothelial cells in vitro. (A) Representative images showing lymphatic meshes 5 hours after culturing with AH or control medium, respectively. Scale bar: 100 μm. Images showing the sites of regression, as indicated by the arrows, are presented in (B). Scale bar: 20 μm. (C) Summarized data assessed in the number and mean size of the meshes, respectively. Assays were performed in triplicates and repeated once. *p < 0.05.
Human Neonatal Microdermal Lecs, supplied by AngioBio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human neonatal microdermal lecs/product/AngioBio Inc
Average 90 stars, based on 1 article reviews
human neonatal microdermal lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ScienCell human lecs
Assessment of IL-7 expression in human LN <t>LECs.</t> (A) Fetal LN sections were stained with fluorescently labeled antibodies against LyveI, MadCAM-1, and CD3. (B) Adult LN sections were stained with antibodies against LyveI, VCAM-1, MadCAM-1, and Pdpn. LyveI+Pdpn+ LECs (blue in left panel and green in right panel) are indicated in the subcapsular sinus (arrows) and LN medulla (*). (C) CD31+Pdpn+ LECs, CD31−Pdpn+ FRCs, and CD31+Pdpn− BECs from human fetal mesenteric LNs were sorted by flow cytometry. IL-7 expression levels were determined by quantitative RT-PCR. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent sorting experiments. (D) Human LN LECs were cultivated and analyzed for IL-7 mRNA expression by quantitative RT-PCR. Cell culture supernatants were collected after 48 hours and analyzed for IL-7 protein by ELISA (right graph). Measurements were carried out in triplicates (mean ± SEM). (E) MACS-isolated human naive CD4+ T cells (2 × 105) were cocultured with <t>human</t> <t>LECs,</t> HUVECs, or supernatant from human LEC cultures in the presence and absence of neutralizing anti–IL-7 antibody. After 48 hours, T-cell survival was analyzed by flow cytometry and is displayed as difference (Δ) to medium control. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent experiments; *P < .05.
Human Lecs, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lecs/product/ScienCell
Average 90 stars, based on 1 article reviews
human lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
PROVITRO GmbH human lecs
Assessment of IL-7 expression in human LN <t>LECs.</t> (A) Fetal LN sections were stained with fluorescently labeled antibodies against LyveI, MadCAM-1, and CD3. (B) Adult LN sections were stained with antibodies against LyveI, VCAM-1, MadCAM-1, and Pdpn. LyveI+Pdpn+ LECs (blue in left panel and green in right panel) are indicated in the subcapsular sinus (arrows) and LN medulla (*). (C) CD31+Pdpn+ LECs, CD31−Pdpn+ FRCs, and CD31+Pdpn− BECs from human fetal mesenteric LNs were sorted by flow cytometry. IL-7 expression levels were determined by quantitative RT-PCR. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent sorting experiments. (D) Human LN LECs were cultivated and analyzed for IL-7 mRNA expression by quantitative RT-PCR. Cell culture supernatants were collected after 48 hours and analyzed for IL-7 protein by ELISA (right graph). Measurements were carried out in triplicates (mean ± SEM). (E) MACS-isolated human naive CD4+ T cells (2 × 105) were cocultured with <t>human</t> <t>LECs,</t> HUVECs, or supernatant from human LEC cultures in the presence and absence of neutralizing anti–IL-7 antibody. After 48 hours, T-cell survival was analyzed by flow cytometry and is displayed as difference (Δ) to medium control. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent experiments; *P < .05.
Human Lecs, supplied by PROVITRO GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lecs/product/PROVITRO GmbH
Average 90 stars, based on 1 article reviews
human lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Lonza primary human lecs hmvecdly
Assessment of IL-7 expression in human LN <t>LECs.</t> (A) Fetal LN sections were stained with fluorescently labeled antibodies against LyveI, MadCAM-1, and CD3. (B) Adult LN sections were stained with antibodies against LyveI, VCAM-1, MadCAM-1, and Pdpn. LyveI+Pdpn+ LECs (blue in left panel and green in right panel) are indicated in the subcapsular sinus (arrows) and LN medulla (*). (C) CD31+Pdpn+ LECs, CD31−Pdpn+ FRCs, and CD31+Pdpn− BECs from human fetal mesenteric LNs were sorted by flow cytometry. IL-7 expression levels were determined by quantitative RT-PCR. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent sorting experiments. (D) Human LN LECs were cultivated and analyzed for IL-7 mRNA expression by quantitative RT-PCR. Cell culture supernatants were collected after 48 hours and analyzed for IL-7 protein by ELISA (right graph). Measurements were carried out in triplicates (mean ± SEM). (E) MACS-isolated human naive CD4+ T cells (2 × 105) were cocultured with <t>human</t> <t>LECs,</t> HUVECs, or supernatant from human LEC cultures in the presence and absence of neutralizing anti–IL-7 antibody. After 48 hours, T-cell survival was analyzed by flow cytometry and is displayed as difference (Δ) to medium control. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent experiments; *P < .05.
Primary Human Lecs Hmvecdly, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary human lecs hmvecdly/product/Lonza
Average 90 stars, based on 1 article reviews
primary human lecs hmvecdly - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Lonza primary human microdermal lymphatic endothelial cells lecs
Assessment of IL-7 expression in human LN <t>LECs.</t> (A) Fetal LN sections were stained with fluorescently labeled antibodies against LyveI, MadCAM-1, and CD3. (B) Adult LN sections were stained with antibodies against LyveI, VCAM-1, MadCAM-1, and Pdpn. LyveI+Pdpn+ LECs (blue in left panel and green in right panel) are indicated in the subcapsular sinus (arrows) and LN medulla (*). (C) CD31+Pdpn+ LECs, CD31−Pdpn+ FRCs, and CD31+Pdpn− BECs from human fetal mesenteric LNs were sorted by flow cytometry. IL-7 expression levels were determined by quantitative RT-PCR. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent sorting experiments. (D) Human LN LECs were cultivated and analyzed for IL-7 mRNA expression by quantitative RT-PCR. Cell culture supernatants were collected after 48 hours and analyzed for IL-7 protein by ELISA (right graph). Measurements were carried out in triplicates (mean ± SEM). (E) MACS-isolated human naive CD4+ T cells (2 × 105) were cocultured with <t>human</t> <t>LECs,</t> HUVECs, or supernatant from human LEC cultures in the presence and absence of neutralizing anti–IL-7 antibody. After 48 hours, T-cell survival was analyzed by flow cytometry and is displayed as difference (Δ) to medium control. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent experiments; *P < .05.
Primary Human Microdermal Lymphatic Endothelial Cells Lecs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary human microdermal lymphatic endothelial cells lecs/product/Lonza
Average 90 stars, based on 1 article reviews
primary human microdermal lymphatic endothelial cells lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Lonza primary human neonatal microvascular becs and lecs
Assessment of IL-7 expression in human LN <t>LECs.</t> (A) Fetal LN sections were stained with fluorescently labeled antibodies against LyveI, MadCAM-1, and CD3. (B) Adult LN sections were stained with antibodies against LyveI, VCAM-1, MadCAM-1, and Pdpn. LyveI+Pdpn+ LECs (blue in left panel and green in right panel) are indicated in the subcapsular sinus (arrows) and LN medulla (*). (C) CD31+Pdpn+ LECs, CD31−Pdpn+ FRCs, and CD31+Pdpn− BECs from human fetal mesenteric LNs were sorted by flow cytometry. IL-7 expression levels were determined by quantitative RT-PCR. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent sorting experiments. (D) Human LN LECs were cultivated and analyzed for IL-7 mRNA expression by quantitative RT-PCR. Cell culture supernatants were collected after 48 hours and analyzed for IL-7 protein by ELISA (right graph). Measurements were carried out in triplicates (mean ± SEM). (E) MACS-isolated human naive CD4+ T cells (2 × 105) were cocultured with <t>human</t> <t>LECs,</t> HUVECs, or supernatant from human LEC cultures in the presence and absence of neutralizing anti–IL-7 antibody. After 48 hours, T-cell survival was analyzed by flow cytometry and is displayed as difference (Δ) to medium control. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent experiments; *P < .05.
Primary Human Neonatal Microvascular Becs And Lecs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary human neonatal microvascular becs and lecs/product/Lonza
Average 90 stars, based on 1 article reviews
primary human neonatal microvascular becs and lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ScienCell human dermal lecs
Hypoxic TAMs promote lymphangiogenesis and LVEM formation. a The function of CM from different macrophage-treated <t>HDLECs</t> on M2-polarized THP-1 macrophages and tumour cells (SiHa) was detected by transwell array in vitro. b Statistical analysis showing the length of tube formation in vitro. Average length of tubes per field were calculated. c Statistical analysis showing the expression of LV and LVEM in mouse footpad tumour. d Representative micrographs showing tube formation assay in vitro of HDLECs pretreated with different macrophage CM for 48 h. Scale bar, 50 μm. e – i Popliteal lymphatic metastasis model was established in female C57BL/6 mice by inoculating the footpad with TC-1 cells (5 × 10 6 ). When footpad tumour size reached 50 mm 3 , macrophage supernatants of different treatment conditions (10 μl) were then injected into the centre of the tumours ( n = 5/group, repeated twice) for 2 weeks daily. After 2 weeks of induction, primary tumours reached a comparable size of ~ 150 mm 3 , and then footpad tumours and popliteal LNs were collected for study. e Representative images of LYVE-1 + lymphatic vessel (red), CD206 + TAMs (green) and DAPI (blue) fluorescence staining in footpad tumour. Images are shown at × 400 magnification (Scale bar, 50 μm). f IHC Staining of CK7 in popliteal LNs. Representative micrographs are shown (Scale bar, 100 μm). Metastasis-positive LNs were identified by staining for epithelial marker CK7. g Photos of mouse popliteal LNs in different macrophage CM-primed tumour ( n = 5/group). h Statistical analysis showing the volume (mm 3 ) of the LNs. i The ratio of metastasis-positive to total dissected popliteal LNs from mice treated with different macrophage supernatants. Error bars represent the mean ± SD of three independent experiments. * P < 0.05. N: Normoxia; H: Hypoxia
Human Dermal Lecs, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dermal lecs/product/ScienCell
Average 90 stars, based on 1 article reviews
human dermal lecs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


(A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic endothelial identity and cell morphology in the channel. (B) Morphologic changes in human dermal microvascular blood endothelial cells (BECs) with lymphatic endothelial cells (LECs) after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.

Journal: Microcirculation (New York, N.Y. : 1994)

Article Title: A bioengineered lymphatic vessel model for studying lymphatic endothelial cell-cell junction and barrier function

doi: 10.1111/micc.12730

Figure Lengend Snippet: (A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic endothelial identity and cell morphology in the channel. (B) Morphologic changes in human dermal microvascular blood endothelial cells (BECs) with lymphatic endothelial cells (LECs) after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.

Article Snippet: In the hollow channel, we seeded human dermal microvascular lymphatic endothelial cells (LECs) to form a biomimetic lymphatic vessel ( ).

Techniques: Expressing, Staining, Diffusion-based Assay, Microscopy, Permeability, Generated, Two Tailed Test

(A) Lymphatic endothelial cells (LECs) in different ECM hydrogels (2D): 2.5 mg/ml collagen 1, 2.5 mg/ml collagen 1 and 150 μg/ml Fibronectin, and no gel (plastic). F-actin and VE-cad were visualized to assess cytoskeletal arrangement and adherens junction formation in each condition. (B) Quantification of the relative junction area was performed, illustrating a significantly lower junction area in cells grown on the 2.5 mg/ml collagen 1 compared to the cells grown directly on plastic. ** p = 0.0017 (Collagen 1 vs. plastic); higher junction area in cells grown on the 2.5 mg/ml collagen 1 + fibronectin compared to the cells grown on collagen 1. * p = 0.0151 (Collagen 1 + fibronectin vs. Collagen 1); not-significant (ns) p = 0.5292 (Collagen 1 + fibronectin vs plastic). One-way ANOVA with Tukey’s HSD tests , n = 6 per group. Data are expressed as mean ± S.E.M. (C) Dynamics of fibronectin on LECs in collagen 1 or collagen 1 + fibronectin gel. On collagen 1 gel, LEC islands with VE-cad expression lacks fibronectin expression. On collagen 1 + fibronectin, fibronectin connects separate LEC islands. (D) At day 4 on Collagen 1 + fibronectin, LECs showed tightened junctions and fibronectin was localized in the junctional area.

Journal: Microcirculation (New York, N.Y. : 1994)

Article Title: A bioengineered lymphatic vessel model for studying lymphatic endothelial cell-cell junction and barrier function

doi: 10.1111/micc.12730

Figure Lengend Snippet: (A) Lymphatic endothelial cells (LECs) in different ECM hydrogels (2D): 2.5 mg/ml collagen 1, 2.5 mg/ml collagen 1 and 150 μg/ml Fibronectin, and no gel (plastic). F-actin and VE-cad were visualized to assess cytoskeletal arrangement and adherens junction formation in each condition. (B) Quantification of the relative junction area was performed, illustrating a significantly lower junction area in cells grown on the 2.5 mg/ml collagen 1 compared to the cells grown directly on plastic. ** p = 0.0017 (Collagen 1 vs. plastic); higher junction area in cells grown on the 2.5 mg/ml collagen 1 + fibronectin compared to the cells grown on collagen 1. * p = 0.0151 (Collagen 1 + fibronectin vs. Collagen 1); not-significant (ns) p = 0.5292 (Collagen 1 + fibronectin vs plastic). One-way ANOVA with Tukey’s HSD tests , n = 6 per group. Data are expressed as mean ± S.E.M. (C) Dynamics of fibronectin on LECs in collagen 1 or collagen 1 + fibronectin gel. On collagen 1 gel, LEC islands with VE-cad expression lacks fibronectin expression. On collagen 1 + fibronectin, fibronectin connects separate LEC islands. (D) At day 4 on Collagen 1 + fibronectin, LECs showed tightened junctions and fibronectin was localized in the junctional area.

Article Snippet: In the hollow channel, we seeded human dermal microvascular lymphatic endothelial cells (LECs) to form a biomimetic lymphatic vessel ( ).

Techniques: Expressing

(A) Activated integrin α5 was visualized in both ECM composition conditions by using anti-integrin α5 antibody (clone: SNAKA51) that can only detect the activated form of the integrin α5. F-actin was also observed in these conditions. (B) LECs in Collagen 1 were pre-treated with anti-integrin α5 antibodies (clone: SNAKA51) antibodies to activate integrin α5 in LECs. The fixed samples were stained with anti-VE-cadherin antibodies, anti-JAM-A antibodies, and phalloidin to visualize adherens junctions and F-actin. (C) Quantification of the relative junction area was performed, illustrating a significantly higher junction area in integrin α5 activated cells compared to the control LECs. ** p = 0.0020; Two tailed unpaired Student t-test, n = 6 per group. Data are expressed as mean ± S.E.M. (D) Control LECs or LECs with activated integrin α5 were seeded in LV-on-chip and cultured for 3 days on the rocking platform. 70 kDa dextran was introduced to the lymphatic lumens. Dextran diffusion was observed at 0 and 1 minutes under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (E) Quantification of the permeability of LEC-generated engineered LVs in collagen 1 with and without integrin α5 activation. ** p = 0.0021. Two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M. (F) This table summarizes our findings regarding LEC permeability and integrin α5 activity. LVs grown in Collagen 1 without any activator treatment showed high LEC permeability and low integrin α5 activity. In contrast, LVs grown in either Collagen 1 + Fibronectin or LVs grown in only Collagen 1 with integrin α5 activator pre-treatment both showed low LEC permeability and high integrin α5 activity.

Journal: Microcirculation (New York, N.Y. : 1994)

Article Title: A bioengineered lymphatic vessel model for studying lymphatic endothelial cell-cell junction and barrier function

doi: 10.1111/micc.12730

Figure Lengend Snippet: (A) Activated integrin α5 was visualized in both ECM composition conditions by using anti-integrin α5 antibody (clone: SNAKA51) that can only detect the activated form of the integrin α5. F-actin was also observed in these conditions. (B) LECs in Collagen 1 were pre-treated with anti-integrin α5 antibodies (clone: SNAKA51) antibodies to activate integrin α5 in LECs. The fixed samples were stained with anti-VE-cadherin antibodies, anti-JAM-A antibodies, and phalloidin to visualize adherens junctions and F-actin. (C) Quantification of the relative junction area was performed, illustrating a significantly higher junction area in integrin α5 activated cells compared to the control LECs. ** p = 0.0020; Two tailed unpaired Student t-test, n = 6 per group. Data are expressed as mean ± S.E.M. (D) Control LECs or LECs with activated integrin α5 were seeded in LV-on-chip and cultured for 3 days on the rocking platform. 70 kDa dextran was introduced to the lymphatic lumens. Dextran diffusion was observed at 0 and 1 minutes under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (E) Quantification of the permeability of LEC-generated engineered LVs in collagen 1 with and without integrin α5 activation. ** p = 0.0021. Two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M. (F) This table summarizes our findings regarding LEC permeability and integrin α5 activity. LVs grown in Collagen 1 without any activator treatment showed high LEC permeability and low integrin α5 activity. In contrast, LVs grown in either Collagen 1 + Fibronectin or LVs grown in only Collagen 1 with integrin α5 activator pre-treatment both showed low LEC permeability and high integrin α5 activity.

Article Snippet: In the hollow channel, we seeded human dermal microvascular lymphatic endothelial cells (LECs) to form a biomimetic lymphatic vessel ( ).

Techniques: Staining, Control, Two Tailed Test, Cell Culture, Diffusion-based Assay, Microscopy, Permeability, Generated, Activation Assay, Activity Assay

Aqueous humor induced the regression of lymphatic tubes formed by human microdermal lymphatic endothelial cells in vitro. (A) Representative images showing lymphatic meshes 5 hours after culturing with AH or control medium, respectively. Scale bar: 100 μm. Images showing the sites of regression, as indicated by the arrows, are presented in (B). Scale bar: 20 μm. (C) Summarized data assessed in the number and mean size of the meshes, respectively. Assays were performed in triplicates and repeated once. *p < 0.05.

Journal: The ocular surface

Article Title: Aqueous humor induces lymphatic regression on the ocular surface

doi: 10.1016/j.jtos.2020.03.002

Figure Lengend Snippet: Aqueous humor induced the regression of lymphatic tubes formed by human microdermal lymphatic endothelial cells in vitro. (A) Representative images showing lymphatic meshes 5 hours after culturing with AH or control medium, respectively. Scale bar: 100 μm. Images showing the sites of regression, as indicated by the arrows, are presented in (B). Scale bar: 20 μm. (C) Summarized data assessed in the number and mean size of the meshes, respectively. Assays were performed in triplicates and repeated once. *p < 0.05.

Article Snippet: Briefly, human neonatal microdermal LECs were purchased from AngioBio (AngioBio Co., Del Mar, CA, USA), and maintained in EBM MV2 growth medium (Promocell, Heidelberg, Germany), supplemented with 10% bovine calf serum (HyClone, Logan, Utah) and 1% penicillin/streptomycin.

Techniques: In Vitro, Control

Assessment of IL-7 expression in human LN LECs. (A) Fetal LN sections were stained with fluorescently labeled antibodies against LyveI, MadCAM-1, and CD3. (B) Adult LN sections were stained with antibodies against LyveI, VCAM-1, MadCAM-1, and Pdpn. LyveI+Pdpn+ LECs (blue in left panel and green in right panel) are indicated in the subcapsular sinus (arrows) and LN medulla (*). (C) CD31+Pdpn+ LECs, CD31−Pdpn+ FRCs, and CD31+Pdpn− BECs from human fetal mesenteric LNs were sorted by flow cytometry. IL-7 expression levels were determined by quantitative RT-PCR. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent sorting experiments. (D) Human LN LECs were cultivated and analyzed for IL-7 mRNA expression by quantitative RT-PCR. Cell culture supernatants were collected after 48 hours and analyzed for IL-7 protein by ELISA (right graph). Measurements were carried out in triplicates (mean ± SEM). (E) MACS-isolated human naive CD4+ T cells (2 × 105) were cocultured with human LECs, HUVECs, or supernatant from human LEC cultures in the presence and absence of neutralizing anti–IL-7 antibody. After 48 hours, T-cell survival was analyzed by flow cytometry and is displayed as difference (Δ) to medium control. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent experiments; *P < .05.

Journal: Blood

Article Title: IL-7-producing stromal cells are critical for lymph node remodeling

doi: 10.1182/blood-2012-03-416859

Figure Lengend Snippet: Assessment of IL-7 expression in human LN LECs. (A) Fetal LN sections were stained with fluorescently labeled antibodies against LyveI, MadCAM-1, and CD3. (B) Adult LN sections were stained with antibodies against LyveI, VCAM-1, MadCAM-1, and Pdpn. LyveI+Pdpn+ LECs (blue in left panel and green in right panel) are indicated in the subcapsular sinus (arrows) and LN medulla (*). (C) CD31+Pdpn+ LECs, CD31−Pdpn+ FRCs, and CD31+Pdpn− BECs from human fetal mesenteric LNs were sorted by flow cytometry. IL-7 expression levels were determined by quantitative RT-PCR. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent sorting experiments. (D) Human LN LECs were cultivated and analyzed for IL-7 mRNA expression by quantitative RT-PCR. Cell culture supernatants were collected after 48 hours and analyzed for IL-7 protein by ELISA (right graph). Measurements were carried out in triplicates (mean ± SEM). (E) MACS-isolated human naive CD4+ T cells (2 × 105) were cocultured with human LECs, HUVECs, or supernatant from human LEC cultures in the presence and absence of neutralizing anti–IL-7 antibody. After 48 hours, T-cell survival was analyzed by flow cytometry and is displayed as difference (Δ) to medium control. Values indicate mean ± SEM from triplicates, representative results from 1 of 2 independent experiments; *P < .05.

Article Snippet: Primary human LECs were obtained from ScienCell.

Techniques: Expressing, Staining, Labeling, Flow Cytometry, Quantitative RT-PCR, Cell Culture, Enzyme-linked Immunosorbent Assay, Isolation, Control

Hypoxic TAMs promote lymphangiogenesis and LVEM formation. a The function of CM from different macrophage-treated HDLECs on M2-polarized THP-1 macrophages and tumour cells (SiHa) was detected by transwell array in vitro. b Statistical analysis showing the length of tube formation in vitro. Average length of tubes per field were calculated. c Statistical analysis showing the expression of LV and LVEM in mouse footpad tumour. d Representative micrographs showing tube formation assay in vitro of HDLECs pretreated with different macrophage CM for 48 h. Scale bar, 50 μm. e – i Popliteal lymphatic metastasis model was established in female C57BL/6 mice by inoculating the footpad with TC-1 cells (5 × 10 6 ). When footpad tumour size reached 50 mm 3 , macrophage supernatants of different treatment conditions (10 μl) were then injected into the centre of the tumours ( n = 5/group, repeated twice) for 2 weeks daily. After 2 weeks of induction, primary tumours reached a comparable size of ~ 150 mm 3 , and then footpad tumours and popliteal LNs were collected for study. e Representative images of LYVE-1 + lymphatic vessel (red), CD206 + TAMs (green) and DAPI (blue) fluorescence staining in footpad tumour. Images are shown at × 400 magnification (Scale bar, 50 μm). f IHC Staining of CK7 in popliteal LNs. Representative micrographs are shown (Scale bar, 100 μm). Metastasis-positive LNs were identified by staining for epithelial marker CK7. g Photos of mouse popliteal LNs in different macrophage CM-primed tumour ( n = 5/group). h Statistical analysis showing the volume (mm 3 ) of the LNs. i The ratio of metastasis-positive to total dissected popliteal LNs from mice treated with different macrophage supernatants. Error bars represent the mean ± SD of three independent experiments. * P < 0.05. N: Normoxia; H: Hypoxia

Journal: Angiogenesis

Article Title: A novel lymphatic pattern promotes metastasis of cervical cancer in a hypoxic tumour-associated macrophage-dependent manner

doi: 10.1007/s10456-020-09766-2

Figure Lengend Snippet: Hypoxic TAMs promote lymphangiogenesis and LVEM formation. a The function of CM from different macrophage-treated HDLECs on M2-polarized THP-1 macrophages and tumour cells (SiHa) was detected by transwell array in vitro. b Statistical analysis showing the length of tube formation in vitro. Average length of tubes per field were calculated. c Statistical analysis showing the expression of LV and LVEM in mouse footpad tumour. d Representative micrographs showing tube formation assay in vitro of HDLECs pretreated with different macrophage CM for 48 h. Scale bar, 50 μm. e – i Popliteal lymphatic metastasis model was established in female C57BL/6 mice by inoculating the footpad with TC-1 cells (5 × 10 6 ). When footpad tumour size reached 50 mm 3 , macrophage supernatants of different treatment conditions (10 μl) were then injected into the centre of the tumours ( n = 5/group, repeated twice) for 2 weeks daily. After 2 weeks of induction, primary tumours reached a comparable size of ~ 150 mm 3 , and then footpad tumours and popliteal LNs were collected for study. e Representative images of LYVE-1 + lymphatic vessel (red), CD206 + TAMs (green) and DAPI (blue) fluorescence staining in footpad tumour. Images are shown at × 400 magnification (Scale bar, 50 μm). f IHC Staining of CK7 in popliteal LNs. Representative micrographs are shown (Scale bar, 100 μm). Metastasis-positive LNs were identified by staining for epithelial marker CK7. g Photos of mouse popliteal LNs in different macrophage CM-primed tumour ( n = 5/group). h Statistical analysis showing the volume (mm 3 ) of the LNs. i The ratio of metastasis-positive to total dissected popliteal LNs from mice treated with different macrophage supernatants. Error bars represent the mean ± SD of three independent experiments. * P < 0.05. N: Normoxia; H: Hypoxia

Article Snippet: Human dermal LECs (HDLECs) were purchased from ScienCell and cultured in endothelial cell medium (ScienCell, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum and endothelial growth medium supplements (ScienCell).

Techniques: In Vitro, Expressing, Tube Formation Assay, Injection, Fluorescence, Staining, Immunohistochemistry, Marker

IL-10 derived from hypoxic TAMs is required to maintain LVEM. a The different cytokines expression profiles among M0-N, M0-H, TAM-N and TAM-H were analysed by cytokine array (RayBio GSM-CAA-4000). b Screening and analysis of the differentially expressed cytokines. c The expressions of the five significant cytokines were analysed by qRT-PCR. d The secretions of the five significant cytokines were analysed by ELISA. e The migration effects of hypoxic TAMs-treated HDLECs on tumour cells (SiHa) and M2-polarized THP-1 macrophages were analysed by transwell assay in vitro. “Blank” represents the medium group. f Representative micrographs showing the tube formation in vitro (Scale bar, 50 μm). g Representative images showing the tube formation in vivo (Scale bar, 100 μm). h Statistical analysis showing the length of tube formation. Average length of tubes per field were calculated. i – l Popliteal lymphatic metastasis model was established in female C57BL/6 mice by inoculating the footpad with TC-1 cells (5 × 10 6 ). When footpad tumour size reached 50 mm 3 , IL-10 (50 ng/ml) or PBS was then injected into the centre of the tumours ( n = 5/group, repeated twice) for 2 weeks daily. After 2 weeks of induction, primary tumours reached a comparable size of ~ 150 mm 3 , and then footpad tumours and popliteal LNs were collected for study. i Representative images of LYVE-1 + lymphatic vessel (red), CD206 + TAMs (green) and DAPI (blue) fluorescence staining in footpad tumour. j Metastasis-positive LNs were identified by IHC staining for epithelial marker CK7. k Statistical analysis showing the expression of peritumoural LV and LVEM in footpad tumour. l Statistical analysis showing the ratio of LNM. Error bars represent the mean ± SD of three independent experiments. ** P < 0.01

Journal: Angiogenesis

Article Title: A novel lymphatic pattern promotes metastasis of cervical cancer in a hypoxic tumour-associated macrophage-dependent manner

doi: 10.1007/s10456-020-09766-2

Figure Lengend Snippet: IL-10 derived from hypoxic TAMs is required to maintain LVEM. a The different cytokines expression profiles among M0-N, M0-H, TAM-N and TAM-H were analysed by cytokine array (RayBio GSM-CAA-4000). b Screening and analysis of the differentially expressed cytokines. c The expressions of the five significant cytokines were analysed by qRT-PCR. d The secretions of the five significant cytokines were analysed by ELISA. e The migration effects of hypoxic TAMs-treated HDLECs on tumour cells (SiHa) and M2-polarized THP-1 macrophages were analysed by transwell assay in vitro. “Blank” represents the medium group. f Representative micrographs showing the tube formation in vitro (Scale bar, 50 μm). g Representative images showing the tube formation in vivo (Scale bar, 100 μm). h Statistical analysis showing the length of tube formation. Average length of tubes per field were calculated. i – l Popliteal lymphatic metastasis model was established in female C57BL/6 mice by inoculating the footpad with TC-1 cells (5 × 10 6 ). When footpad tumour size reached 50 mm 3 , IL-10 (50 ng/ml) or PBS was then injected into the centre of the tumours ( n = 5/group, repeated twice) for 2 weeks daily. After 2 weeks of induction, primary tumours reached a comparable size of ~ 150 mm 3 , and then footpad tumours and popliteal LNs were collected for study. i Representative images of LYVE-1 + lymphatic vessel (red), CD206 + TAMs (green) and DAPI (blue) fluorescence staining in footpad tumour. j Metastasis-positive LNs were identified by IHC staining for epithelial marker CK7. k Statistical analysis showing the expression of peritumoural LV and LVEM in footpad tumour. l Statistical analysis showing the ratio of LNM. Error bars represent the mean ± SD of three independent experiments. ** P < 0.01

Article Snippet: Human dermal LECs (HDLECs) were purchased from ScienCell and cultured in endothelial cell medium (ScienCell, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum and endothelial growth medium supplements (ScienCell).

Techniques: Derivative Assay, Expressing, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Migration, Transwell Assay, In Vitro, In Vivo, Injection, Fluorescence, Staining, Immunohistochemistry, Marker

CCL1 mediates the migration of TAMs towards LECs in the formation of LVEM. a Multiple related chemokines were screened in IL-10-activated LECs by qRT-PCR. b Levels of CCL1 secreted by IL-10-activated LECs were measured by ELISA. c The migration effects of CCL1 on tumour cells (SiHa) and M2-polarized THP-1 macrophages were significantly decreased by blockade of CCR8 on receptor cells (siRNA or CCR8 antagonist MC148) or adding anti-CCL1 neutralization antibody in IL-10-activated LEC CM. d – f Popliteal lymphatic metastasis model was established in female C57BL/6 mice by inoculating the footpad with TC-1 cells (5 × 10 6 ). When footpad tumour size reached 50 mm 3 , CCL1 (50 ng/ml) or PBS was then injected into the centre of the tumours ( n = 5/group, repeated twice) for 2 weeks daily. After 2 weeks of induction, primary tumours reached a comparable size of ~ 150 mm 3 , and then popliteal LNs were collected for study. d Representative images of LYVE-1 + lymphatic vessel (red), CD206 + TAMs (green) and DAPI (blue) fluorescence staining in footpad tumour. e IHC Staining of CK7 in popliteal LNs from mice treated with CCL1 (Scale bar, 100 μm). f Statistical analysis showing the ratio of LNM. Error bars represent the mean ± SD of three independent experiments. ** P < 0.01. * P < 0.05

Journal: Angiogenesis

Article Title: A novel lymphatic pattern promotes metastasis of cervical cancer in a hypoxic tumour-associated macrophage-dependent manner

doi: 10.1007/s10456-020-09766-2

Figure Lengend Snippet: CCL1 mediates the migration of TAMs towards LECs in the formation of LVEM. a Multiple related chemokines were screened in IL-10-activated LECs by qRT-PCR. b Levels of CCL1 secreted by IL-10-activated LECs were measured by ELISA. c The migration effects of CCL1 on tumour cells (SiHa) and M2-polarized THP-1 macrophages were significantly decreased by blockade of CCR8 on receptor cells (siRNA or CCR8 antagonist MC148) or adding anti-CCL1 neutralization antibody in IL-10-activated LEC CM. d – f Popliteal lymphatic metastasis model was established in female C57BL/6 mice by inoculating the footpad with TC-1 cells (5 × 10 6 ). When footpad tumour size reached 50 mm 3 , CCL1 (50 ng/ml) or PBS was then injected into the centre of the tumours ( n = 5/group, repeated twice) for 2 weeks daily. After 2 weeks of induction, primary tumours reached a comparable size of ~ 150 mm 3 , and then popliteal LNs were collected for study. d Representative images of LYVE-1 + lymphatic vessel (red), CD206 + TAMs (green) and DAPI (blue) fluorescence staining in footpad tumour. e IHC Staining of CK7 in popliteal LNs from mice treated with CCL1 (Scale bar, 100 μm). f Statistical analysis showing the ratio of LNM. Error bars represent the mean ± SD of three independent experiments. ** P < 0.01. * P < 0.05

Article Snippet: Human dermal LECs (HDLECs) were purchased from ScienCell and cultured in endothelial cell medium (ScienCell, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum and endothelial growth medium supplements (ScienCell).

Techniques: Migration, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Neutralization, Injection, Fluorescence, Staining, Immunohistochemistry

Sp1 high LECs are fundamental to LVEM formation and lymphatic metastasis. a Bioinformatic prediction and screening of potential transcription factors of CCL1. b RNA sequence of the predicted Sp1-binding site to CCL1 was TCCCCTCCCCC. A dual-luciferase reporter assay system was performed to demonstrate the direct binding of Sp1 to the CCL1 promoter region. Transient co-transfection of pcDNA3.1-Sp1 construct with CCL1 promoter into both 293T cells and HDLECs resulted in a significant increase in firefly luciferase activity relative to co-transfection of pcDNA3.1-NC construct with CCL1 promoter or the negative control. c EILSA analysis showed that CCL1 upregulation was detected in Sp1-transduced HDLEC CM, and CCL1 was decreased in Sp1-silenced HDLEC CM. d Representative micrographs of the tube formation assay in vitro (upper panel) and in vivo (lower panel) of HDLECs with stable overexpression or silencing of Sp1 (Scale bar, 100 μm). e Statistical analysis showing the length of tube formation. Average length of tubes per field were calculated. f The migration effects of M2-polarized THP-1 macrophages and tumour cells (SiHa) towards CM of HDLECs with stable overexpression or silencing of Sp1 were detected by transwell array in vitro. g Immunofluorescence staining was applied to analyse Sp1 (purple), LYVE-1 (red), CD163 (green) and DAPI (blue) expression in CSCC tissues (Scale bar, 100 μm). h The correlation between Sp1 expression and LVEM density was statistically analysed by Pearson’s coefficient test (red line, r = 0.5846, P = 0.0009; blue line, r = 0.1018, P = 0.2465). i Immunofluorescence staining was applied to analyse Sp1 (purple), CCL1 (red), CD163 (green) and DAPI (blue) expression in CSCC tissues (Scale bar, 50 μm). j The correlation between Sp1 and CCL1 expression was statistically analysed by Pearson’s coefficient test ( r = 0.4126, P < 0.001). Error bars represent the mean ± SD of three independent experiments. *, P < 0.05

Journal: Angiogenesis

Article Title: A novel lymphatic pattern promotes metastasis of cervical cancer in a hypoxic tumour-associated macrophage-dependent manner

doi: 10.1007/s10456-020-09766-2

Figure Lengend Snippet: Sp1 high LECs are fundamental to LVEM formation and lymphatic metastasis. a Bioinformatic prediction and screening of potential transcription factors of CCL1. b RNA sequence of the predicted Sp1-binding site to CCL1 was TCCCCTCCCCC. A dual-luciferase reporter assay system was performed to demonstrate the direct binding of Sp1 to the CCL1 promoter region. Transient co-transfection of pcDNA3.1-Sp1 construct with CCL1 promoter into both 293T cells and HDLECs resulted in a significant increase in firefly luciferase activity relative to co-transfection of pcDNA3.1-NC construct with CCL1 promoter or the negative control. c EILSA analysis showed that CCL1 upregulation was detected in Sp1-transduced HDLEC CM, and CCL1 was decreased in Sp1-silenced HDLEC CM. d Representative micrographs of the tube formation assay in vitro (upper panel) and in vivo (lower panel) of HDLECs with stable overexpression or silencing of Sp1 (Scale bar, 100 μm). e Statistical analysis showing the length of tube formation. Average length of tubes per field were calculated. f The migration effects of M2-polarized THP-1 macrophages and tumour cells (SiHa) towards CM of HDLECs with stable overexpression or silencing of Sp1 were detected by transwell array in vitro. g Immunofluorescence staining was applied to analyse Sp1 (purple), LYVE-1 (red), CD163 (green) and DAPI (blue) expression in CSCC tissues (Scale bar, 100 μm). h The correlation between Sp1 expression and LVEM density was statistically analysed by Pearson’s coefficient test (red line, r = 0.5846, P = 0.0009; blue line, r = 0.1018, P = 0.2465). i Immunofluorescence staining was applied to analyse Sp1 (purple), CCL1 (red), CD163 (green) and DAPI (blue) expression in CSCC tissues (Scale bar, 50 μm). j The correlation between Sp1 and CCL1 expression was statistically analysed by Pearson’s coefficient test ( r = 0.4126, P < 0.001). Error bars represent the mean ± SD of three independent experiments. *, P < 0.05

Article Snippet: Human dermal LECs (HDLECs) were purchased from ScienCell and cultured in endothelial cell medium (ScienCell, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum and endothelial growth medium supplements (ScienCell).

Techniques: Sequencing, Binding Assay, Luciferase, Reporter Assay, Cotransfection, Construct, Activity Assay, Negative Control, Tube Formation Assay, In Vitro, In Vivo, Over Expression, Migration, Immunofluorescence, Staining, Expressing